DK3423076T3 - Topisk cyclosporinholdige formuleringer og anvendelser deraf - Google Patents

Topisk cyclosporinholdige formuleringer og anvendelser deraf Download PDF

Info

Publication number
DK3423076T3
DK3423076T3 DK17760643.1T DK17760643T DK3423076T3 DK 3423076 T3 DK3423076 T3 DK 3423076T3 DK 17760643 T DK17760643 T DK 17760643T DK 3423076 T3 DK3423076 T3 DK 3423076T3
Authority
DK
Denmark
Prior art keywords
containing formulations
topical cyclosporine
cyclosporine
topical
formulations
Prior art date
Application number
DK17760643.1T
Other languages
English (en)
Inventor
Eugene J Mcnally
Sidney L Weiss
Ashim K Mitra
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59744365&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3423076(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Application granted granted Critical
Publication of DK3423076T3 publication Critical patent/DK3423076T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17760643.1T 2016-02-29 2017-02-28 Topisk cyclosporinholdige formuleringer og anvendelser deraf DK3423076T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662301576P 2016-02-29 2016-02-29
US201662302058P 2016-03-01 2016-03-01
US201662302730P 2016-03-02 2016-03-02
US201662311177P 2016-03-21 2016-03-21
PCT/US2017/020008 WO2017151657A1 (en) 2016-02-29 2017-02-28 Topical cyclosporine-containing formulations and uses thereof

Publications (1)

Publication Number Publication Date
DK3423076T3 true DK3423076T3 (da) 2024-07-08

Family

ID=59744365

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17760643.1T DK3423076T3 (da) 2016-02-29 2017-02-28 Topisk cyclosporinholdige formuleringer og anvendelser deraf

Country Status (21)

Country Link
US (4) US10918694B2 (da)
EP (2) EP4410312A3 (da)
JP (3) JP7072517B2 (da)
KR (1) KR102766771B1 (da)
CN (2) CN119185511A (da)
AU (2) AU2017227585C1 (da)
BR (1) BR112018067946A8 (da)
CA (1) CA3015626A1 (da)
DK (1) DK3423076T3 (da)
ES (1) ES2981702T3 (da)
FI (1) FI3423076T3 (da)
IL (1) IL268056A (da)
MX (2) MX2018010395A (da)
NZ (2) NZ785158A (da)
PL (1) PL3423076T3 (da)
PT (1) PT3423076T (da)
RU (1) RU2747455C2 (da)
SA (1) SA519410114B1 (da)
SG (1) SG11201906729RA (da)
WO (1) WO2017151657A1 (da)
ZA (1) ZA201904704B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
EP3373976B1 (en) 2015-11-10 2024-01-03 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
US10918694B2 (en) 2016-02-29 2021-02-16 Sun Pharma Global Fze Topical cyclosporine-containing formulations and uses thereof
CN112957450A (zh) * 2019-12-20 2021-06-15 艾棣维欣(苏州)生物制药有限公司 一种难溶性药物的水溶液及其制备方法
AU2022295164A1 (en) 2021-06-14 2024-01-25 Sun Pharmaceutical Industries Limited Cyclosporine formulations for use in patients undergoing cataract surgery
WO2021224901A2 (en) * 2021-08-20 2021-11-11 Sun Pharmaceutical Industries Limited Stable cyclosporine ophthalmic formulation and manufacturing process thereof
WO2024042550A1 (en) * 2022-08-25 2024-02-29 Sentiss Pharma Private Limited Ophthalmic combination composition
JP2025538061A (ja) 2022-11-04 2025-11-26 クラリス バイオ インコーポレイテッド クロマカリムの局所眼内送達
EP4719350A1 (en) 2023-05-29 2026-04-08 Sun Pharmaceutical Industries Limited Stable cyclosporine ophthalmic formulation and manufacturing process thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69307505T2 (de) 1992-05-13 1997-07-24 Sandoz-Patent-Gmbh, 79539 Loerrach Opthalmische zusammensetzungen enthaltend ein cyclosporin
NZ247516A (en) 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5484597A (en) 1993-07-30 1996-01-16 Chesebrough-Pond's Usa Co. Clear hydroalcholic cosmetic microemulsions
NZ280689A (en) 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US7678836B2 (en) 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
HRP20040354B1 (en) 2001-10-19 2012-10-31 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
WO2004069181A2 (en) 2003-02-03 2004-08-19 Pharmacia Corporation Composition for the treatment of intraocular pressure
JP2004238346A (ja) 2003-02-07 2004-08-26 Shiono Chemical Co Ltd トラニラストの安定な水溶液製剤
WO2004096261A1 (es) 2003-05-02 2004-11-11 Arturo Jimenez Bayardo Metodo para preparar una solucion acuosa de ciclosporina-a y solucion acuosa resultante
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
DE602004017477D1 (de) 2004-11-09 2008-12-11 Novagali Pharma Sa Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
US20090209599A1 (en) 2005-06-09 2009-08-20 Yoko Endo Eye drop containing roflumilast
EP1890677A4 (en) 2005-06-16 2013-01-30 Myriad Genetics Inc PHARMACEUTICAL COMPOSITIONS AND THEIR USE
US20070015691A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
AU2006270041B2 (en) 2005-07-18 2011-08-18 Minu, Llc Enhanced ocular neuroprotection/neurostimulation
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
CA2650422A1 (en) 2006-04-24 2007-11-08 Nanocarrier Co., Ltd. Process for producing polymer micelles encapsulating low molecular weight drugs
WO2007136134A1 (ja) 2006-05-23 2007-11-29 Nanocarrier Co., Ltd. 疎水性薬物内包ポリマーミセルの製造方法
CN101489574A (zh) 2006-07-18 2009-07-22 那野伽利阿株式会社 内包生理活性多肽或蛋白质的高分子聚合物胶束及其制造方法
US20100310462A1 (en) 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US8512687B2 (en) 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
EP2193795B1 (en) 2007-08-29 2014-10-01 Wakamoto Pharmaceutical Co., Ltd. Latanoprost-containing aqueous pharmaceutical composition
MX2007011165A (es) 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
ES2667945T3 (es) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
JP2011508776A (ja) 2008-01-04 2011-03-17 アルコン ファーマシューティカルズ リミテッド 安定な水性シクロスポリン組成物
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2278953B1 (en) 2008-05-28 2016-05-04 Alcon Research, Ltd Self-preserved emulsions
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
AP2012006053A0 (en) 2009-06-02 2012-02-29 Brian Charles Keller Pure peg-lipid conjugates.
EP2440185B1 (en) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
EP2478906A4 (en) 2009-09-17 2013-02-20 Senju Pharma Co AQUEOUS OPHTHALMIC DROPS THAT CONTAIN LATANOPROST, AND A METHOD OF INHIBITING ADSORPTION OF LATANOPROST ON A RESIN
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
EP2538965B1 (en) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
WO2011138801A1 (en) 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd. Novel ophthalmic compositions
US20130065888A1 (en) 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
US9278132B2 (en) 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
MX2014013714A (es) 2012-05-11 2015-08-10 Cipla Ltd Composicion farmaceutica.
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
WO2014126997A1 (en) 2013-02-13 2014-08-21 The Research Foundation For The State University Of New York Glaucoma treatment
AU2015264181A1 (en) * 2014-05-23 2016-12-01 Ocular Technologies Sarl Topical formulations and uses thereof
US20150352176A1 (en) 2014-06-06 2015-12-10 Newport Research, Inc. Oil-free and fat-free aqueous suspensions of cyclosporin
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20180133217A1 (en) 2015-05-04 2018-05-17 Ocular Technologies Sarl Topical formulations and uses thereof
EP3373976B1 (en) 2015-11-10 2024-01-03 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
EP3373924A4 (en) 2015-11-12 2019-06-19 Sun Pharma Global FZE Topical formulations and uses thereof
US10918694B2 (en) 2016-02-29 2021-02-16 Sun Pharma Global Fze Topical cyclosporine-containing formulations and uses thereof
WO2017152129A2 (en) 2016-03-03 2017-09-08 Ocular Technologies Sarl Treatment of glaucoma and/or retinal diseases and formulations useful therefore
AU2022295164A1 (en) * 2021-06-14 2024-01-25 Sun Pharmaceutical Industries Limited Cyclosporine formulations for use in patients undergoing cataract surgery

Also Published As

Publication number Publication date
JP2022110054A (ja) 2022-07-28
AU2017227585B2 (en) 2022-02-17
US20190060397A1 (en) 2019-02-28
MX2024010721A (es) 2024-09-10
AU2022203135A1 (en) 2022-06-02
EP3423076A1 (en) 2019-01-09
AU2017227585C1 (en) 2022-05-26
US20240197818A1 (en) 2024-06-20
IL268056A (en) 2019-08-29
NZ785158A (en) 2025-03-28
CN119185511A (zh) 2024-12-27
KR102766771B1 (ko) 2025-02-14
MX2018010395A (es) 2018-11-29
US20210145924A1 (en) 2021-05-20
SA519410114B1 (ar) 2024-02-11
KR20180117661A (ko) 2018-10-29
PL3423076T3 (pl) 2024-08-19
JP7072517B2 (ja) 2022-05-20
JP7547411B2 (ja) 2024-09-09
US11951153B2 (en) 2024-04-09
BR112018067946A2 (pt) 2019-01-15
EP3423076B1 (en) 2024-04-17
EP3423076A4 (en) 2019-11-27
RU2019130403A (ru) 2021-03-26
US10918694B2 (en) 2021-02-16
EP4410312A2 (en) 2024-08-07
CN109843316A (zh) 2019-06-04
ZA201904704B (en) 2022-10-26
AU2017227585A1 (en) 2018-10-18
ES2981702T3 (es) 2024-10-10
NZ755442A (en) 2023-04-28
JP2019507154A (ja) 2019-03-14
FI3423076T3 (fi) 2024-06-24
EP4410312A3 (en) 2024-11-20
RU2747455C2 (ru) 2021-05-05
AU2022203135B2 (en) 2025-09-11
PT3423076T (pt) 2024-07-01
JP2024161602A (ja) 2024-11-19
WO2017151657A1 (en) 2017-09-08
BR112018067946A8 (pt) 2022-11-08
RU2019130403A3 (da) 2021-03-26
CA3015626A1 (en) 2017-09-08
SG11201906729RA (en) 2019-08-27
US20230083458A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
IL268697A (en) Formulations
DK3688162T3 (da) Formuleringer
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3478693T3 (da) Boronsyrederivater og terapeutiske anvendelser deraf
DK3423076T3 (da) Topisk cyclosporinholdige formuleringer og anvendelser deraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3559227T3 (da) Proteasevarianter og anvendelser deraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3494119T3 (da) Forbindelser og sammensætninger og anvendelser deraf
EP3328353A4 (en) TOPICAL SKIN FORMULATIONS
DK3420039T3 (da) Printningsformuleringer og fremgangsmåder
SI3672948T1 (sl) Piridinamin-piridon in spojine pirimidinamin-piridona
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
EP3383912A4 (en) TOPICAL FORMULATIONS
DK3324938T3 (da) Topikale formuleringer og behandlinger
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3337506T3 (da) Kombinationer og anvendelser deraf
IL268583A (en) Preparations and methods for use on the skin
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
MA49905A (fr) Polyesteramines et polyesterquats
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf
EP3328354A4 (en) TOPICAL SKIN FORMULATIONS
HUE063178T2 (hu) Kopanlizib formulációi